menu
    • menu
    [{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"China Medical University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Atropine","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kubota Pharmaceutical \/ China Medical University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Kubota Pharmaceutical \/ China Medical University Hospital"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kubota Pharmaceutical

                            Japan arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Kubota Pharmaceutical

                            Japan arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : China Medical University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Electronic Spectacles Versus Low Dose Atropine in Young Myopes

                            Details : Atropine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Myopia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 13, 2023

                            Lead Product(s) : Atropine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : China Medical University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Santen Pharmaceutical

                            Japan arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Santen Pharmaceutical

                            Japan arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Gla...

                            Details : Latanoprost is a HPAPI drug candidate, which is currently being evaluated in clinical studies for the treatment of Glaucoma, Open-Angle.

                            Product Name : Undisclosed

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            February 04, 2021

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth